Your browser is no longer supported. Please, upgrade your browser.
Settings
LOXO Loxo Oncology, Inc. daily Stock Chart
LOXO [NASD]
Loxo Oncology, Inc.
Index- P/E- EPS (ttm)-2.09 Insider Own4.12% Shs Outstand30.75M Perf Week-
Market Cap- Forward P/E- EPS next Y-3.38 Insider Trans- Shs Float27.36M Perf Month-
Income- PEG- EPS next Q-0.81 Inst Own99.70% Short Float3.75% Perf Quarter-
Sales144.80M P/S- EPS this Y59.30% Inst Trans- Short Ratio- Perf Half Y-
Book/sh12.41 P/B- EPS next Y-56.50% ROA- Target Price225.00 Perf Year-
Cash/sh- P/C- EPS next 5Y37.00% ROE- 52W Range- - - Perf YTD-
Dividend- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low- ATR-
Employees59 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility- -
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume- Prev Close-
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume- Price-
Recom2.40 SMA20- SMA50- SMA200- Volume0 Change-
Apr-17-19 10:14AM  Double Top Spells Trouble for 3 Health Care Stocks Investopedia
Mar-14-19 01:13PM  Steven Cohen Takes Stake in Aptevo Therapeutics GuruFocus.com
Feb-20-19 10:13AM  Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's notes; stable outlook Moody's
Feb-19-19 08:00AM  Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-15-19 04:10PM  Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company Moody's
11:43AM  Bayer gains full Vitrakvi rights from Eli Lilly's Loxo Reuters
09:23AM  Lilly Completes Acquisition of Loxo Oncology PR Newswire
Feb-13-19 08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Feb-07-19 07:31AM  5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure Motley Fool
Feb-06-19 04:33PM  Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal TheStreet.com
03:04PM  Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript Motley Fool
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Naider Avi Z.DirectorDec 13Buy138.92725100,716126,843Dec 17 05:07 PM
Bilenker Joshua H.President & CEODec 11Option Exercise13.6710,000136,700174,407Dec 12 05:12 PM
Burstein JenniferSenior VP of FinanceDec 11Option Exercise11.351,25014,1881,250Dec 12 05:14 PM
Van Naarden JacobChief Business OfficerDec 11Option Exercise7.5711,50087,05120,700Dec 12 05:17 PM
Van Naarden JacobChief Business OfficerDec 11Sale137.354,500618,08013,700Dec 12 05:17 PM
Burstein JenniferSenior VP of FinanceDec 11Sale137.431,250171,7920Dec 12 05:14 PM
Bilenker Joshua H.President & CEODec 11Sale137.4210,0001,374,237164,407Dec 12 05:12 PM
Bilenker Joshua H.President & CEODec 10Option Exercise13.6710,000136,700174,407Dec 12 05:12 PM
Burstein JenniferSenior VP of FinanceDec 10Option Exercise11.351,25014,1881,250Dec 12 05:14 PM
Van Naarden JacobChief Business OfficerDec 10Option Exercise13.674,50061,51518,200Dec 12 05:17 PM
Van Naarden JacobChief Business OfficerDec 10Sale133.654,500601,43413,700Dec 12 05:17 PM
Burstein JenniferSenior VP of FinanceDec 10Sale133.671,250167,0840Dec 12 05:14 PM
Bilenker Joshua H.President & CEODec 10Sale133.5210,0001,335,198164,407Dec 12 05:12 PM
Bilenker Joshua H.President & CEONov 27Option Exercise13.6710,000136,700174,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 27Option Exercise11.351,25014,1881,250Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 27Option Exercise8.234,50037,03118,200Nov 28 05:13 PM
Van Naarden JacobChief Business OfficerNov 27Sale141.664,500637,48113,700Nov 28 05:13 PM
Burstein JenniferSenior VP of FinanceNov 27Sale142.281,250177,8510Nov 28 05:09 PM
Bilenker Joshua H.President & CEONov 27Sale141.3410,0001,413,418164,407Nov 28 05:08 PM
Bilenker Joshua H.President & CEONov 26Option Exercise2.2039,00085,709174,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 26Option Exercise11.351,25014,1881,250Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 26Option Exercise3.655,50020,06419,200Nov 28 05:13 PM
Van Naarden JacobChief Business OfficerNov 26Sale153.135,500842,22413,700Nov 28 05:13 PM
Burstein JenniferSenior VP of FinanceNov 26Sale153.081,250191,3560Nov 28 05:09 PM
Bilenker Joshua H.President & CEONov 26Sale153.1810,0001,531,829164,407Nov 28 05:08 PM
Bilenker Joshua H.President & CEOOct 04Option Exercise3.6510,00036,480145,407Oct 05 04:42 PM
Burstein JenniferSenior VP of FinanceOct 04Option Exercise11.351,25014,1881,250Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 04Option Exercise3.654,50016,41618,200Oct 05 04:46 PM
Van Naarden JacobChief Business OfficerOct 04Sale162.644,500731,88413,700Oct 05 04:46 PM
Burstein JenniferSenior VP of FinanceOct 04Sale162.641,250203,3040Oct 05 04:44 PM
Bilenker Joshua H.President & CEOOct 04Sale162.6210,0001,626,246135,407Oct 05 04:42 PM
Burstein JenniferSenior VP of FinanceOct 03Option Exercise11.351,25014,1881,250Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 03Option Exercise3.655,50020,06419,200Oct 05 04:46 PM
Van Naarden JacobChief Business OfficerOct 03Sale167.165,500919,37813,700Oct 05 04:46 PM
Burstein JenniferSenior VP of FinanceOct 03Sale167.201,250208,9960Oct 05 04:44 PM
Bilenker Joshua H.President & CEOOct 03Sale168.187,0951,193,254135,407Oct 05 04:42 PM
Kunkel Lori AnneDirectorOct 01Option Exercise3.655,00018,2405,000Oct 03 05:05 PM
Kunkel Lori AnneDirectorOct 01Sale170.375,000851,8290Oct 03 05:05 PM
Burstein JenniferSenior VP of FinanceSep 13Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 13Option Exercise3.654,50016,41618,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 13Option Exercise1.8110,00018,067145,407Sep 14 06:17 PM
Bilenker Joshua H.President & CEOSep 13Sale165.9810,0001,659,805135,407Sep 14 06:17 PM
Van Naarden JacobChief Business OfficerSep 13Sale165.984,500746,90313,700Sep 14 06:14 PM
Burstein JenniferSenior VP of FinanceSep 13Sale166.021,250207,5230Sep 14 06:19 PM
Burstein JenniferSenior VP of FinanceSep 12Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 12Option Exercise3.655,50020,06419,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 12Option Exercise1.1810,00011,840145,407Sep 14 06:17 PM
Bilenker Joshua H.President & CEOSep 12Sale166.4210,0001,664,159135,407Sep 14 06:17 PM
Van Naarden JacobChief Business OfficerSep 12Sale166.605,500916,27613,700Sep 14 06:14 PM
Burstein JenniferSenior VP of FinanceSep 12Sale167.891,250209,8690Sep 14 06:19 PM
Bilenker Joshua H.President & CEOAug 14Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 14Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 14Option Exercise3.654,50016,41618,200Aug 15 05:27 PM
Van Naarden JacobChief Business OfficerAug 14Sale159.924,500719,64213,700Aug 15 05:27 PM
Burstein JenniferSenior VP of FinanceAug 14Sale160.221,250200,2790Aug 15 05:25 PM
Bilenker Joshua H.President & CEOAug 14Sale159.9110,0001,599,089135,407Aug 15 05:23 PM
Bilenker Joshua H.President & CEOAug 13Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 13Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 13Option Exercise3.655,50020,06419,200Aug 15 05:27 PM
Van Naarden JacobChief Business OfficerAug 13Sale158.875,500873,80413,700Aug 15 05:27 PM
Burstein JenniferSenior VP of FinanceAug 13Sale158.261,250197,8270Aug 15 05:25 PM
Bilenker Joshua H.President & CEOAug 13Sale158.9110,0001,589,092135,407Aug 15 05:23 PM